Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Aaron P. Rapoport"'
Autor:
Jean A. Yared, Elizabeth Hutnick, Ashraf Badros, Mehmet H. Kocoglu, Nancy M. Hardy, Forat Lutfi, Søren M. Bentzen, Jonathan Siglin, Aaron P. Rapoport, Firas El Chaer, Carl Shanholtz, Kathleen Ruehle, Vivek Kesari, Noa G. Holtzman, Hao Xie, Haroon Ahmad, Saurabh Dahiya, Ali Bukhari, Natalie Gahres
Publikováno v:
Neuro Oncol
Background CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR-T) has emerged as effective for relapsed/refractory large B-cell lymphoma (R/R LBCL). The neurologic toxicity seen with CAR-T, referred to as immune effector cell–associat
Autor:
Adam M. Petrich, Koen van Besien, Justin Kline, Krishna Rao, Sreenivasa Nattam, Ajay Major, Amy S. Kimball, Aaron P. Rapoport, Kenneth J. Cohen, Bethany G. Sleckman, Sonali M. Smith, Theodore Karrison, Paul A. S. Fishkin
Publikováno v:
Haematologica. 107(7)
The PI3K/Akt/mTOR (PAM) axis is constitutively activated in multiple lymphoma subtypes and is a promising therapeutic target. The mTOR inhibitor temsirolimus (TEM) and the immunomodulatory agent lenalidomide (LEN) have overlapping effects within the
Autor:
Leona Holmberg, Ajay K. Nooka, David Avigan, Robert J. Soiffer, Nancy L. Geller, Hillard M. Lazarus, Lynne Uhl, Kenneth C. Anderson, Jane S. Reese, Jacalyn Rosenblatt, Nina Shah, Steven M. Devine, David J. Chung, Bryon D. Johnson, Juan Wu, Dimitra Karagkouni, David H. McKenna, Ioannis S. Vlachos, Thinle Chodon, Giulia Cheloni, Natalie S. Callander, Brent R. Logan, Lina Bisharat, Alan Howard, Ehsan Malek, Nikhil C. Munshi, James W. Young, Yvonne A. Efebera, Aaron P. Rapoport, Meera Mohan, Marcelo C. Pasquini, Dina Stroopinsky, Lynn O'Donnell, Edmund K. Waller, Philip L. McCarthy, Peiman Hematti, Adam Mendizabal
Publikováno v:
Blood. 138:899-899
In a prior phase 2 study, personalized cancer vaccination with autologous dendritic cells (DCs) fused with primary MM tumor cells (DC/MM fusions) induced the expansion of circulating MM-reactive lymphocytes and was associated with conversion to compl
Autor:
A. Badros, Dianna S. Howard, Barry R. Meisenberg, Donna E. Reece, David H. Vesole, Joanne Filicko-O'Hara, Jasleen K Randhawa, Neal Flomenberg, Parameswaran Hari, Aaron P. Rapoport, Gordon L. Phillips
Publikováno v:
Bone Marrow Transplantation. 54:293-299
The most common preparative regimen for autologous transplantation (ASCT) in myeloma (MM) consists of melphalan 200 mg/m2 (MEL 200). Higher doses of melphalan 220–260 mg/m2, although relatively well tolerated, have not shown significant improvement
Autor:
Ahmet Dogan, Mehmet Hakan Kocoglu, Sunita Philip, Ning Ma, Olga Goloubeva, Elizabeth Hyjek, Cameron Dell, Alexander M. Lesokhin, Aaron P. Rapoport, Emily Lederer, Ashraf Z. Badros, Zeba N. Singh, Todd Milliron
Publikováno v:
Blood. 130:1189-1197
Programmed death 1 (PD-1) receptor and its ligand (PD-L1) facilitate immune evasion in multiple myeloma (MM). We hypothesized that pembrolizumab, PD-1-antibody, can enhance antimyeloma cellular immunity generated by pomalidomide, leading to improved
Autor:
Ajay Major, Justin Kline, Kenneth J. Cohen, Adam M. Petrich, Amy S. Kimball, Bethany G. Sleckman, Koen van Besien, Paul A. S. Fishkin, Aaron P. Rapoport, Theodore Karrison, Sreenivasa Nattam, Sonali M. Smith
Publikováno v:
Blood. 136:43-44
Background Targeting the PI3K/Akt/mTOR axis in relapsed lymphomas is of interest based on constitutive activation in many lymphoma subtypes, and has had varying degrees of success. We previously showed that the first generation mTOR inhibitor, temsir
Autor:
Ali Bukhari, Linda Ridge, Nancy M. Hardy, Kathleen Ruehle, Saurabh Dahiya, Jason K. Molitoris, Natalie Gahres, Santanu Samanta, Forat Lutfi, Aaron P. Rapoport, Hanan Alkhaldi, Justin N. Malinou, Olga Goloubeva, Nicolette Minas, Pranshu Mohindra, Gabriela Sanchez-Petitto, Jean Yared
Publikováno v:
Blood. 136:20-21
Background: Nonmyeloablative (NMA) and reduced-intensity conditioning (RIC) regimens are offered for patients with hematologic malignancies requiring allogeneic stem cell transplantation (HSCT) but are not candidates for myeloablative conditioning (M
Autor:
Lina Bisharat, David J. Chung, Kelly A. O’Brien, Peiman Hematti, Robert J. Soiffer, David Avigan, David H. McKenna, Lynne Uhl, Jiaxi Zhu, Michele Herman, Natalie S. Callander, Nancy L. Geller, Yvonne A. Efebera, James W. Young, Courtney Nelson, Jacalyn Rosenblatt, Thinle Chodon, Aaron P. Rapoport, Pallawi Torka, Marcelo C. Pasquini, Binod Dhakal, Hillard M. Lazarus, Nina Shah, Ajay K. Nooka, Juan Wu, Lynn O'Donnell, Edmund K. Waller, Dina Stroopinsky, Brent R. Logan
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:S62-S63
BMT CTN 1401 is an academically led randomized study of a personalized cancer vaccine in which the combination of DC/MM fusion vaccine and lenalidomide maintenance after autoHCT is compared with maintenance alone as upfront treatment of MM (NCT#02728
Autor:
Michael Kleinberg, Brandon Cooper, Xiaoxuan Fan, Michelle Fleyshman, Jonathan Siglin, Rena G. Lapidus, Dong Won Kim, Aaron P. Rapoport, Forat Lutfi, Saurabh Dahiya, Diego de Miguel Perez, Ali Bukhari, David Gottlieb, Gabriela Sanchez-Petitto
Publikováno v:
Blood
Introduction:The spread of SARS-CoV-2 virus continues to pose a major public health threat. Patients with cancer are thought to be at increased risk from SARS-COV-2 infection due to the immunodeficiency that results from the underlying neoplasm and t
Autor:
Alison R. Sehgal, David B. Miklos, Loretta J. Nastoupil, Abhinav Deol, Julie M. Vose, Javier Munoz, Patrick M. Reagan, N. Nora Bennani, Saurabh Dahiya, Sattva S. Neelapu, Jay Y. Spiegel, Brian T. Hill, Julio C. Chavez, Aaron P. Rapoport, Frederick L. Locke, Joseph P. McGuirk, Olalekan O. Oluwole, Charalambos Andreadis, Yi Lin, Andre Goy, Lazaros J. Lekakis, Michael D. Jain, Matthew A. Lunning, Armin Ghobadi, Gao Feng, Miriam T. Jacobs
Publikováno v:
Blood. 134:245-245
MDJ and MTJ contributed equally; FLL and AG contributed equally. Introduction Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are autologous anti-CD19 CAR T-cell therapies approved for the treatment of adults with relapsed or refrac